Menu Search
Equities

Myriad Genetics Inc

MYD:HAM

Myriad Genetics Inc

Actions
  • Price (EUR)16.20
  • Today's Change-0.40 / -2.41%
  • Shares traded200.00
  • 1 Year change-2.41%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Myriad Genetics Inc had net income fall 135.09% from a loss of 112.00m to a larger loss of 263.30m despite a 11.03% increase in revenues from 678.40m to 753.20m. An increase in the cost of goods sold as a percentage of sales from 29.78% to 31.36% was a component in the falling net income despite rising revenues.
Gross margin69.06%
Net profit margin-19.35%
Operating margin-19.43%
Return on assets-13.66%
Return on equity-21.03%
Return on investment-16.32%
More ▼

Cash flow in USDView more

In 2023, Myriad Genetics Inc increased its cash reserves by 112.20%, or 74.50m. Cash Flow from Financing totalled 152.90m or 20.30% of revenues. In addition the company used 110.90m for operations while cash from investing totalled 31.90m.
Cash flow per share-1.09
Price/Cash flow per share--
Book value per share8.15
Tangible book value per share1.48
More ▼

Balance sheet in USDView more

Myriad Genetics Inc uses little debt in its capital structure as supported by a debt to capital ratio of 4.98%.
Current ratio1.96
Quick ratio1.78
Total debt/total equity0.0524
Total debt/total capital0.0498
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		40.85
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.